REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Regeneron Provides Update on Biologics License Application for Odronextamab

25 3 2024 07:00:02 提供 Nasdaq GlobeNewswire

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

12 3 2024 21:30:22 提供 Nasdaq GlobeNewswire

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

11 3 2024 07:00:23 提供 Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

08 3 2024 07:00:26 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

28 2 2024 09:48:56 提供 NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 2 2024 09:48:37 提供 NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

23 2 2024 09:45:04 提供 NetDania Notify

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

23 2 2024 01:00:00 提供 Nasdaq GlobeNewswire

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

21 2 2024 07:00:13 提供 Nasdaq GlobeNewswire

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

16 2 2024 00:59:00 提供 Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

06 2 2024 16:05:00 提供 Nasdaq GlobeNewswire

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

02 2 2024 06:30:01 提供 Nasdaq GlobeNewswire

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

02 2 2024 06:00:04 提供 Nasdaq GlobeNewswire

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

30 1 2024 07:00:41 提供 Nasdaq GlobeNewswire

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

25 1 2024 14:29:00 提供 Nasdaq GlobeNewswire

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

24 1 2024 12:00:00 提供 Nasdaq GlobeNewswire

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

16 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

05 1 2024 16:05:00 提供 Nasdaq GlobeNewswire

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

18 12 2023 16:05:00 提供 Nasdaq GlobeNewswire

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

11 12 2023 07:30:00 提供 Nasdaq GlobeNewswire